Reshape Lifesciences Stock Cash Flow From Operations
| RSLS Stock | USD 3.92 0.72 22.50% |
Fundamental analysis of ReShape Lifesciences allows traders to better anticipate movements in ReShape Lifesciences' stock price by examining its financial health and performance throughout various phases of its business cycle.
ReShape | Cash Flow From Operations | Build AI portfolio with ReShape Stock |
ReShape Lifesciences Company Cash Flow From Operations Analysis
ReShape Lifesciences' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current ReShape Lifesciences Cash Flow From Operations | (4.43 M) |
Most of ReShape Lifesciences' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ReShape Lifesciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
ReShape Cash Flow From Operations Driver Correlations
Understanding the fundamental principles of building solid financial models for ReShape Lifesciences is extremely important. It helps to project a fair market value of ReShape Stock properly, considering its historical fundamentals such as Cash Flow From Operations. Since ReShape Lifesciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ReShape Lifesciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ReShape Lifesciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
ReShape Discontinued Operations
Discontinued Operations |
|
In accordance with the recently published financial statements, ReShape Lifesciences has (4.43 Million) in Cash Flow From Operations. This is 100.84% lower than that of the Health Care Equipment & Supplies sector and 101.21% lower than that of the Health Care industry. The cash flow from operations for all United States stocks is 100.46% higher than that of the company.
ReShape Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ReShape Lifesciences' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ReShape Lifesciences could also be used in its relative valuation, which is a method of valuing ReShape Lifesciences by comparing valuation metrics of similar companies.ReShape Lifesciences is currently under evaluation in cash flow from operations category among its peers.
ReShape Lifesciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of ReShape Lifesciences from analyzing ReShape Lifesciences' financial statements. These drivers represent accounts that assess ReShape Lifesciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of ReShape Lifesciences' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 670.7M | 439.3M | 448.0M | 71.5M | 82.2M | 78.1M | |
| Enterprise Value | 668.5M | 436.8M | 425.5M | 67.8M | 78.0M | 74.1M |
ReShape Lifesciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, ReShape Lifesciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to ReShape Lifesciences' managers, analysts, and investors.Environmental | Governance | Social |
ReShape Fundamentals
| Return On Equity | -1.2 | ||||
| Return On Asset | -0.53 | ||||
| Profit Margin | (0.48) % | ||||
| Operating Margin | (1.65) % | ||||
| Current Valuation | 5.25 M | ||||
| Shares Outstanding | 2.39 M | ||||
| Shares Owned By Insiders | 10.62 % | ||||
| Shares Owned By Institutions | 1.10 % | ||||
| Number Of Shares Shorted | 209.03 K | ||||
| Price To Book | 6.21 X | ||||
| Price To Sales | 1.30 X | ||||
| Revenue | 8.01 M | ||||
| Gross Profit | 4.57 M | ||||
| EBITDA | (6.67 M) | ||||
| Net Income | (7.13 M) | ||||
| Cash And Equivalents | 11.49 M | ||||
| Cash Per Share | 0.51 X | ||||
| Total Debt | 967 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 2.12 X | ||||
| Book Value Per Share | 9.24 X | ||||
| Cash Flow From Operations | (4.43 M) | ||||
| Short Ratio | 0.48 X | ||||
| Earnings Per Share | 264.12 X | ||||
| Price To Earnings To Growth | (12.12) X | ||||
| Target Price | 1.0 | ||||
| Number Of Employees | 17 | ||||
| Beta | 1.9 | ||||
| Market Capitalization | 9.35 M | ||||
| Total Asset | 4.79 M | ||||
| Retained Earnings | (642.7 M) | ||||
| Working Capital | (397 K) | ||||
| Net Asset | 4.79 M |
About ReShape Lifesciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ReShape Lifesciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ReShape Lifesciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ReShape Lifesciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for ReShape Stock Analysis
When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.